340 related articles for article (PubMed ID: 23433768)
1. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
[TBL] [Abstract][Full Text] [Related]
2. Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.
Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Michishita I
J Atheroscler Thromb; 2016 Jul; 23(7):848-56. PubMed ID: 26797266
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.
Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Liu G; Dong Q; Li JJ
Ann Med; 2015; 47(5):386-93. PubMed ID: 26153823
[TBL] [Abstract][Full Text] [Related]
4. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
5. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ
Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415
[TBL] [Abstract][Full Text] [Related]
6. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
[TBL] [Abstract][Full Text] [Related]
7. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
[TBL] [Abstract][Full Text] [Related]
8. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
9. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
10. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
11. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Terashima M; Michishita I
Am J Cardiol; 2013 Jun; 111(11):1570-5. PubMed ID: 23497779
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
[TBL] [Abstract][Full Text] [Related]
14. Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease.
Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Michishita I
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):320-6. PubMed ID: 23324995
[TBL] [Abstract][Full Text] [Related]
15. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
[TBL] [Abstract][Full Text] [Related]
16. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis.
Nozue T; Yamamoto S; Tohyama S; Umezawa S; Kunishima T; Sato A; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Sozu T; Terashima M; Michishita I
Am Heart J; 2012 Feb; 163(2):191-9.e1. PubMed ID: 22305836
[TBL] [Abstract][Full Text] [Related]
17. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
[TBL] [Abstract][Full Text] [Related]
18. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
19. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
Guo YL; Liu J; Xu RX; Zhu CG; Wu NQ; Jiang LX; Li JJ
Clin Drug Investig; 2013 Dec; 33(12):877-83. PubMed ID: 24114461
[TBL] [Abstract][Full Text] [Related]
20. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease.
Li S; Guo YL; Xu RX; Zhang Y; Zhu CG; Sun J; Qing P; Wu NQ; Jiang LX; Li JJ
Atherosclerosis; 2014 Jun; 234(2):441-5. PubMed ID: 24769476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
